Home › Companies › RECURSION PHARMACEUTICALS, INC. › 2025-2026
Compiled from SEC Form N-PX filings and RECURSION PHARMACEUTICALS, INC.’s Form 8-K, filed 2026-06-18 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore RECURSION PHARMACEUTICALS, INC. in the interactive database Compare manager voting policies
These tallies are RECURSION PHARMACEUTICALS, INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Najat Khan, Ph.D. | 210,437,751 | -- | -- | 27,907,256 | 126,675,762 | Majority: yes |
| Elect Director: Franziska Michor, Ph.D. | 208,124,737 | -- | -- | 30,220,270 | 126,675,762 | Majority: yes |
| Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast: | 206,171,008 | 30,893,147 | 1,280,852 | -- | 126,675,762 | Majority: yes |
| Proposal 3: The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 was ratified, with the following votes cast: | 361,743,500 | 2,148,771 | 1,128,498 | -- | -- | Majority: yes |
Source: RECURSION PHARMACEUTICALS, INC., Form 8-K, filed with the SEC on 2026-06-18 — read the filing on EDGAR.
Each item below shows how the 299 asset managers that disclosed a RECURSION PHARMACEUTICALS, INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of RECURSION PHARMACEUTICALS, INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2026-06-17.
Combines 5 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast:”): 206,171,008 for, 30,893,147 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 530,628,653 outstanding shares: 39% for, 6% against (45% of the company cast a for/against vote).
The 284 asset managers below cast 79% of the shares they voted on this item FOR (52,169,225 for, 14,074,892 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,672,964 | 20,551 | 0 | 0 | For |
| MIC Capital Management UK LLP | 8,451,758 | 0 | 0 | 0 | For |
| Amova Asset Management Co., Ltd. | 0 | 5,384,024 | 0 | 0 | Against |
| State Street | 4,774,833 | 39,340 | 0 | 0 | For |
| BlackRock | 4,209,304 | 70,780 | 0 | 0 | For |
| Lingotto Investment Management LLP | 4,062,729 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 3,064,357 | 0 | 0 | 0 | For |
| ARK Investment Management LLC | 3,034,418 | 0 | 0 | 0 | For |
| Northern Trust | 2,035,455 | 132,271 | 0 | 0 | For |
| Goldman Sachs | 1,014,273 | 53,053 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 945,102 | 0 | 0 | Against |
| Man Group plc | 843,285 | 0 | 0 | 0 | For |
| CAPITAL FUND MANAGEMENT S.A. | 818,892 | 0 | 0 | 0 | For |
| Charles Schwab | 769,997 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 762,609 | 0 | 0 | Against |
| Vestmark Advisory Solutions, Inc. | 702,311 | 0 | 0 | 0 | For |
| ARK Venture Fund | 620,765 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 610,133 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 547,595 | 0 | 0 | Against |
| UBS | 0 | 533,148 | 0 | 0 | Against |
| Fidelity | 508,395 | 0 | 0 | 0 | For |
| Lincoln Financial | 370,761 | 91,230 | 0 | 0 | For |
| AllianceBernstein | 0 | 448,204 | 0 | 0 | Against |
| Lazard | 0 | 389,686 | 0 | 0 | Against |
| Equitable | 69,563 | 296,949 | 0 | 0 | Against |
Showing the 25 largest of 284 asset managers. See all 284 in the interactive database.
Meeting held 2026-06-17.
Combines 3 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“Proposal 3: The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 was ratified, with the following votes cast:”): 361,743,500 for, 2,148,771 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 530,628,653 outstanding shares: 68% for, 0.5% against (69% of the company cast a for/against vote).
The 55 asset managers below cast 100% of the shares they voted on this item FOR (15,063,647 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,358,445 | 0 | 0 | 0 | For |
| State Street | 1,883,659 | 0 | 0 | 0 | For |
| ARK Venture Fund | 620,765 | 0 | 0 | 0 | For |
| BlackRock | 594,714 | 0 | 0 | 0 | For |
| Lincoln Financial | 461,991 | 0 | 0 | 0 | For |
| Fidelity | 439,172 | 0 | 0 | 0 | For |
| Charles Schwab | 383,865 | 0 | 0 | 0 | For |
| Equitable | 366,512 | 0 | 0 | 0 | For |
| First Trust | 324,103 | 0 | 0 | 0 | For |
| FundVantage Trust | 311,293 | 0 | 0 | 0 | For |
| Guggenheim | 204,222 | 0 | 0 | 0 | For |
| American Century | 132,750 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 102,692 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 87,100 | 0 | 0 | 0 | For |
| Global X | 78,729 | 0 | 0 | 0 | For |
| SEI | 78,300 | 0 | 0 | 0 | For |
| Themes ETF Trust | 77,000 | 0 | 0 | 0 | For |
| JPMorgan | 66,229 | 0 | 0 | 0 | For |
| DWS | 64,004 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 62,666 | 0 | 0 | 0 | For |
| Brighthouse | 14,326 | 0 | 44,555 | 0 | Abstain |
| AIG/SunAmerica | 43,089 | 0 | 0 | 0 | For |
| Calvert | 37,513 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 37,311 | 0 | 0 | 0 | For |
| ProShares | 35,438 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
Meeting held 2026-06-17.
Combines 5 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“Elect Director: Najat Khan, Ph.D.”): 210,437,751 for, 27,907,256 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 530,628,653 outstanding shares: 40% for, 5% withheld (45% of the company cast a for/withheld vote).
The 53 asset managers below cast 100% of the shares they voted on this item FOR (13,524,020 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,358,442 | 0 | 3 | 0 | For |
| State Street | 1,881,499 | 0 | 2,160 | 0 | For |
| ARK Venture Fund | 620,765 | 0 | 0 | 0 | For |
| BlackRock | 594,714 | 0 | 0 | 0 | For |
| Lincoln Financial | 370,761 | 0 | 91,230 | 0 | For |
| Fidelity | 439,172 | 0 | 0 | 0 | For |
| Charles Schwab | 383,865 | 0 | 0 | 0 | For |
| Equitable | 366,512 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 324,103 | 0 | Abstain |
| FundVantage Trust | 0 | 0 | 311,293 | 0 | Abstain |
| Guggenheim | 0 | 0 | 204,222 | 0 | Abstain |
| American Century | 0 | 0 | 132,750 | 0 | Abstain |
| Bridge Builder Trust | 87,100 | 0 | 0 | 0 | For |
| Global X | 78,729 | 0 | 0 | 0 | For |
| SEI | 78,300 | 0 | 0 | 0 | For |
| Themes ETF Trust | 0 | 0 | 77,000 | 0 | Abstain |
| JPMorgan | 66,229 | 0 | 0 | 0 | For |
| DWS | 0 | 0 | 64,004 | 0 | Abstain |
| AMERICAN BEACON FUNDS | 62,666 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 58,881 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 43,089 | 0 | Abstain |
| Calvert | 0 | 0 | 37,513 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 37,311 | 0 | Abstain |
| ProShares | 0 | 0 | 35,438 | 0 | Abstain |
| Venerable Variable Insurance Trust | 34,542 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.
Meeting held 2026-06-17.
Combines 5 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“Elect Director: Franziska Michor, Ph.D.”): 208,124,737 for, 30,220,270 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 530,628,653 outstanding shares: 39% for, 6% withheld (45% of the company cast a for/withheld vote).
The 53 asset managers below cast 100% of the shares they voted on this item FOR (13,227,070 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,358,442 | 0 | 3 | 0 | For |
| State Street | 1,881,499 | 0 | 2,160 | 0 | For |
| ARK Venture Fund | 620,765 | 0 | 0 | 0 | For |
| BlackRock | 594,714 | 0 | 0 | 0 | For |
| Lincoln Financial | 370,761 | 0 | 91,230 | 0 | For |
| Fidelity | 439,172 | 0 | 0 | 0 | For |
| Charles Schwab | 383,865 | 0 | 0 | 0 | For |
| Equitable | 69,563 | 0 | 296,949 | 0 | Abstain |
| First Trust | 0 | 0 | 324,103 | 0 | Abstain |
| FundVantage Trust | 0 | 0 | 311,293 | 0 | Abstain |
| Guggenheim | 0 | 0 | 204,222 | 0 | Abstain |
| American Century | 0 | 0 | 132,750 | 0 | Abstain |
| Bridge Builder Trust | 87,100 | 0 | 0 | 0 | For |
| Global X | 78,729 | 0 | 0 | 0 | For |
| SEI | 78,300 | 0 | 0 | 0 | For |
| Themes ETF Trust | 0 | 0 | 77,000 | 0 | Abstain |
| JPMorgan | 66,229 | 0 | 0 | 0 | For |
| DWS | 0 | 0 | 64,004 | 0 | Abstain |
| AMERICAN BEACON FUNDS | 62,666 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 58,881 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 43,089 | 0 | Abstain |
| Calvert | 0 | 0 | 37,513 | 0 | Abstain |
| Direxion Shares ETF Trust | 0 | 0 | 37,311 | 0 | Abstain |
| ProShares | 0 | 0 | 35,438 | 0 | Abstain |
| Venerable Variable Insurance Trust | 34,542 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.
Meeting held 2026-06-17.
87% Majority: yes · of votes cast
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast:”): 206,171,008 for, 30,893,147 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 530,628,653 outstanding shares: 39% for, 6% against (45% of the company cast a for/against vote).
The 6 asset managers below cast 0.1% of the shares they voted on this item FOR (1,570 for, 13,679,273 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SOFTBANK GROUP CORP. | 0 | 13,636,515 | 0 | 0 | Against |
| TD Waterhouse Canada Inc. | 0 | 38,131 | 0 | 0 | Against |
| Bellevue Group AG | 0 | 4,627 | 0 | 0 | Against |
| LOUISBOURG INVESTMENTS INC. | 1,170 | 0 | 0 | 0 | For |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma | 400 | 0 | 0 | 0 | For |
| Torrey Growth & Income Advisors | 0 | 0 | 0 | 0 | -- |
Meeting held 2025-06-18 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).
99% Majority: yes · of votes cast
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast:”): 239,911,332 for, 3,242,536 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 530,628,653 outstanding shares: 45.2% for, 0.7% against (45.8% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (17,500 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| OSBORNE PARTNERS CAPITAL MANAGEMENT, LLC | 14,500 | 0 | 0 | 0 | For |
| Slow Capital, Inc. | 3,000 | 0 | 0 | 0 | For |
Ranked by the number of RECURSION PHARMACEUTICALS, INC. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 530,628,653 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.39% |
| 2 | MIC Capital Management UK LLP | 1.59% |
| 3 | Amova Asset Management Co., Ltd. | 1.01% |
| 4 | State Street | 0.91% |
| 5 | BlackRock | 0.81% |
| 6 | Lingotto Investment Management LLP | 0.77% |
| 7 | MARSHALL WACE, LLP | 0.58% |
| 8 | ARK Investment Management LLC | 0.57% |
| 9 | Northern Trust | 0.41% |
| 10 | Goldman Sachs | 0.20% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 8.89% | 13F |
| BlackRock | 8.14% | 13F |
| ARK Investment Management LLC | 7.03% | 13G |
| Vanguard Portfolio Management | 5.91% | 13G |
| State Street | 5.37% | 13F |
| BAILLIE GIFFORD & CO | 4.48% | 13G |
| Zachary Bogue | 2.57% | DEF14A |
| Blake Borgeson | 1.20% | DEF14A |
| Goldman Sachs | 1.14% | 13F |
| Morgan Stanley | 1.07% | 13F |
Percentages above are of 530,628,653 shares outstanding, as reported by RECURSION PHARMACEUTICALS, INC. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RECURSION PHARMACEUTICALS, INC.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At RECURSION PHARMACEUTICALS, INC.'s shareholder meeting held 2026-06-17, in the 2025-2026 proxy season, 299 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,052 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2026 PROXY STATEMENT. — FOR was 87% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: RECURSION PHARMACEUTICALS, INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-18.
RECURSION PHARMACEUTICALS, INC. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).